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Background. Our objective was to determine virological and clinical characteristics associated with virological failure in human immunodeficiency virus (HIV)-infected patients switching to darunavir/ritonavir (DRV/r) monotherapy.
Methods. The main outcome was virologic rebound, defined as 2 consecutive measurements of HIV-1 plasma RNA viral load (VL) .50 copies/mL. A logistic model was used to investigate which variables were predictive of a virologic rebound at weeks 48 (W48) and 96 (W96).
Results. Receiving DRV/r monotherapy was associated with virologic rebound at W48 (P 5 .016) and W96 (P 5 .002), comparable to triple therapy. In the DRV/r monotherapy group, at W48, having a VL .50 copies/mL at day 0 and even a baseline ultrasensitive VL .1 copy/mL were predictive factors to virologic rebound (P 5 .042 and P 5 .025, respectively). At W96, shorter time of prior antiretrovial therapy (ART) exposure (odds ratio [OR] 5 2.93 per 5 years decrease; P 5 .006), higher HIV-1 DNA at day 0 (OR 5 2.66 per 1 log 10 copies/10 6 cells increase; P 5 .04) and adherence ,100% (OR 5 3.84 vs 100%; P 5 .02) were associated with an increased risk of rebound.
Conclusions. Factors associated with virological failure in patients receiving DRV/r monotherapy were having an initial blip, shorter time of antiretroviral treatment before monotherapy, and an adherence ,100% during monotherapy. The importance of prior duration exposure to ART was in agreement with the impact of HIV-1 blood reservoir and VL level at baseline.
All guidelines for the use of antiretroviral agents in human immunodeficiency virus type 1 (HIV-1)-infected patients recommend currently achieving a plasma HIV-1 RNA viral load (VL) of ,50 copies/mL under treatment. In European and French guidelines, virological rebound is defined as confirmed plasma HIV RNA .50 copies/mL 6 months after starting therapy (initiation or modification) in patients who remain on antiretrovial therapy (ART) [1, 2] . Several trials have investigated monotherapy strategies in naive patients and in patients with fully suppressed VL [3] [4] [5] [6] . A few studies have shown long-term efficacy for such a strategy, although on a limited number of patients [3, 4] . A recent review supported the idea that a majority of patients with prolonged viral suppression on highly active antiretroviral therapy (HAART) can successfully be treated with protease inhibitor monotherapy [7] .
Nevertheless, the duration of the period of viral suppression and the role of other factors have not been clearly identified as markers of monotherapy success. In particular, the recent development of an ultrasensitive assay questioned whether a viral suppression ,50 copies/mL or ,1 copy/mL is required for patients to successfully receive such a monotherapy. Indeed, using ultrasensitive VL assays, some studies have shown that HIV-1 residual viremia can be detected in most HIV-1-infected patients on antiretroviral therapy despite an apparent suppression of VL (HIV-1 RNA ,50 copies/mL) [8] . In addition, a recent study suggested that residual viremia could have an impact on virological response in treated patients [9] .
The French study MONOI is a 96-week, multicenter, randomized open-label trial with a primary endpoint at week 48 (W48). While the results demonstrated the high efficacy rate of a darunavir monotherapy strategy in experienced patients, with .85% patients maintaining suppressed VL, the noninferiority of darunavir/ritonavir (DRV/r) monotherapy to DRV/r triple therapy could not be fully demonstrated [5] .
Our objective was to determine virological and clinical characteristics of patients who can successfully receive such a boosted protease monotherapy. Among other variables that could be predictive to a virologic rebound, we specifically investigated pretherapeutic VL, HIV-DNA at baseline, and baseline HIV-1 RNA measured by ultrasensitive assay. We studied the predictive ability of these variables to identify patients with low risk of virologic rebound in a short-term (week 48) and longterm (week 96) efficacy analysis.
METHODS

Patients
A total of 225 HIV-1-infected patients were randomized in the MONOI trial (113 in the triple therapy arm and 112 in the monotherapy arm). This study comprised a first phase where DRV/r 600/100 mg twice a day was introduced for 8 weeks as a component of a triple-drug regimen in replacement of the protease inhibitor (PI), nonnucleoside reverse transcriptase inhibitor (NNRTI), or third nucleoside reverse transcriptase inhibitor (NRTI). Patients whose HIV-1 VL remained ,50 copies/mL 4 weeks after darunavir (DRV) induction were randomly assigned 1:1 at day 0 (D0) to continue the triple-drug DRVcontaining regimen (DRV triple therapy) or to stop the 2 NRTIs (DRV monotherapy). After screening (week -10), study evaluations were completed at week -4, randomization, weeks 4 and 8, and every 8 weeks thereafter for the duration of the study. In particular, ultrasensitive quantification assay for HIV-1 RNA was performed on plasma samples collected at screening, D0, and W48. The study population consisted of HIV-1-infected patients at least 18 years of age receiving a triple antiretroviral drug regimen. All patients had plasma HIV-1 RNA ,400 copies/mL for the last 18 months, based on at least 4 VL measurements, and ,50 copies/mL at screening. Patients had no history of virologic failure while receiving a PIcontaining regimen, a documented CD4 lymphocyte nadir .50 cells/mm 3 , and acceptable laboratory results at screening.
Patients with a history of HIV-related neurological disease or with hepatitis B coinfection could not be enrolled. Randomization was centralized and stratified by HIV-1 RNA level (,100 000 vs $100 000 copies/mL) prior to first antiretroviral treatment.
HIV-1 RNA Ultrasensitive and HIV-1 DNA Quantification Assays
Plasma samples were collected in EDTA tubes and stored at 280°C until quantification. Residual plasma viremia was measured as previously described [10] with a limit of quantification of 1 copy/mL at screening, D0, and W48. For further analysis, screening and D0 samples were defined as baseline ultrasensitive VL. According to the baseline ultrasensitive VL results, we defined 2 groups: screening and D0 values of ultrasensitive VL ,1 copy/mL, and others. Whole blood was collected at D0 and cellular HIV-1 DNA was quantified as previously described [11] .
Outcome and Variables
Considering both European and French guidelines, the primary outcome in this study was virologic rebound defined as 2 consecutive measurements of HIV-1 RNA plasma .50 copies/mL. The second HIV-1 RNA measurement can be obtained either at a confirmation visit within 2 weeks or at the next study visit.
Although the MONOI trial defined virologic failure as a confirmed plasma HIV-1 RNA level .400 copies/mL [5] , in fact many patients with an initial HIV-1 RNA level between 50 and 400 copies/mL had a second confirmatory test performed within 2 weeks. In addition, primary endpoints often used the threshold of 50 copies/mL; we used a failure definition of a confirmed plasma HIV-1 RNA level .50 copies/mL for the current analysis. In this analysis, which is based on the intent-to-treat population, we only considered rebounds occurring before any treatment changes. A secondary endpoint was defined as at least 1 measurement of HIV-1 RNA .50 copies/mL occurring before any treatment changes. Adherence was measured by a questionnaire including a 4-day recall. An adherence rate of 100% was defined as no missed doses declared during the previous 4 days at entry and weeks 4, 24, and 48 for the W48 analysis, and also week 96 for the W96 analysis. Full adherence (100% adherence) was defined as patients reporting no missing doses at all evaluations.
Statistical Analysis
Fisher exact and Wilcoxon tests were used to compare discrete and continuous variables. A logistic model was used to investigate which variables were predictive to a virologic rebound at weeks 48 and 96. We investigated the following variables: age; sex; CD4 nadir; duration of HIV infection; duration of previous NRTI, NNRTI, and PI exposure; pretherapeutic VL; strata of pretherapeutic VL; global adherence; randomized group; type of combination at screening (PI-containing regimen versus other); HIV-1 RNA at D0 (VL .50 copies/mL after having VL ,50 copies/mL at screening was defined as viremia blip); baseline HIV-1 RNA measured by ultrasensitive assay; and log 10 HIV-DNA at D0. All variables providing a P value , .20 in the univariate analysis may be selected by the stepwise procedure to build multivariate models. Final multivariate models included only variables significantly (P , .05) associated with virologic outcomes. The Kaplan-Meier method was used to compare the time to virologic rebound in the 2 randomized groups. The SAS statistical software program, version 9.2, was used for analyses.
RESULTS
Baseline characteristics of patients were similar between the 2 treatment groups (Table 1) . Data on baseline ultrasensitive VL assays were available in 224 of the 225 patients randomized (triple-drug regimen, n 5 113; monotherapy, n 5 111) and data on HIV-DNA were available in 193 patients (triple-drug regimen, n 5 96; monotherapy, n 5 97). Overall, 45.5% (102 of 224) of patients had a baseline ultrasensitive VL ,1 copy/mL and the median HIV-DNA at D0 was 2.46 log 10 copies/10 6 cells (interquartile range [IQR], 2.1-2.8 log 10 ). The proportion of patients in the 2 groups of baseline ultrasensitive VL did not differ significantly between the 2 treatment groups (P 5 .18), and there was no influence of the treatment received at screening on the level of ultrasensitive VL at baseline (P 5 .87). Patients with baseline ultrasensitive VL ,1 copy/mL had lower median HIV-1 DNA (2.26 vs 2.56 log 10 copies/10 6 cells; P 5 .008) and a longer median exposure to PI therapy (6.6 vs 4.3 years; P 5 .02) than others. Notably, 8 patients had a VL level between 50 and 400 copies/mL at D0, but all patients had VL ,50 copies/mL at W4. From D0 to W48, 16 patients experienced a virologic rebound as defined above (14 in the DRV/r monotherapy group and 2 in the 2 NRTI 1 DRV/r group; P 5 .002) and in all of them the second VL .50 copies/mL result was obtained at a confirmation visit. Overall, receiving monotherapy (odds ratio [OR] 5 7.16; 95% confidence interval [CI], 1.8-48.7) and having a viremia blip at D0 (OR 5 7.11; 95% CI, 1.2-39.2) were independently associated with an increased risk of rebound by W48, whereas baseline ultrasensitive VL ,1 copy/mL (OR 5 0.18; 95% CI, .03-.73) was independently associated with a decreased risk ( Table 2 ). Considering only patients in the DRV/r monotherapy group, only having a blip at D0 (OR 5 10.0; 95% CI, 1.63-62.7) was associated with a virologic rebound by W48 (model 1). However, a second model (model 2) was fitted to the data removing the HIV-1 DNA variable from the stepwise procedure because among the 16 patients with missing HIV-1 DNA data, 3 patients experienced a virologic rebound. In model 2, experiencing a blip at D0 (OR 5 7.84; 95% CI, 1.22-52.2) and having a baseline ultrasensitive VL ,1 copy/mL (OR 5 0.24; 95% CI, .05-.86) were independently associated with an increased and decreased risk of rebound, respectively.
From D0 to W96, a total of 33 patients experienced at least 1 virologic rebound, 24 (21.4%) in the DRV/r group and 9 (8.0%) in the 2 NRTI 1 DRV/r group (P 5 .005). For those 33 patients, the median viral load at confirmation of virologic rebound was 2.27 log 10 copies/mL (IQR, 1.9-2.6 log 10 ). Monotherapy group (OR 5 4.81; 95% CI, 1.91-13.7), shorter time of prior ART exposure (OR 5 2.11 per 5 years decrease; 95% CI, 1.23-3.80), and higher HIV-1 DNA at D0 (OR 5 1.97 per 1 log 10 increase; 95% CI, 1.10-3.57) were independently associated with an increased risk of rebound by W96 (Table 3) . Overall, in patients experiencing a rebound the median of prior ART exposure was 5.1 years (IQR, 3.1-9.9) and the median of HIV-1 DNA was 2.66 log 10 copies/10 6 cells (IQR, 2.5-2.9) while in patients without rebound the median of prior ART exposure was 8.9 (IQR, 3.9-11.5) years and the median of HIV-1 DNA was 2.35 log 10 copies/10 6 cells (IQR, 2.1-2.7). In the DRV/r monotherapy group, prior shorter exposure to ART (OR 5 2.93 per 5 years decrease; 95% CI, 1.43-6.66), high HIV-1 DNA at D0 (OR 5 2.66 per 1 log 10 increase; 95% CI, 1.11-7.48), and difficulty in adherence (OR 5 3.84; 95% CI, 1.29-12.49) were associated with rebound by W96. In the DRV/r monotherapy group, in patients experiencing a rebound the median of prior ART exposure was 5.3 years (IQR, 3.4-9.9) and the median of HIV-1 DNA was 2.62 log 10 copies/10 6 cells (IQR, 2.4-2.9), whereas in patients without rebound the median of prior ART exposure was 9.9 (IQR, 6.2-11.7) years and the median of HIV-1 DNA was 2.31 log 10 copies/10 6 cells (IQR, 2.1-2.7).
The monotherapy group had a significantly shorter time to virologic rebound than did the 2 NRTI 1 DRV/r group (Figure 1 log-rank test, P 5 .004). The estimated probability of remaining free of virologic rebound at W96 was .77 in the monotherapy group and .91 in the 2 NRTI 1 DRV/r group. Due to the small number of outcomes, it was not possible to investigate specific factors associated with rebound in patients randomized in the triple-drug regimen in both the W48 and W96 analyses.
Importantly, in this open-label study, we determined whether patients experiencing a first HIV-1 RNA .50 copies/mL and randomized in the monotherapy group were more often retested within 2 weeks than patients randomized in the 2 NRTI 1 DRV/r group. From D0 to W48, 62% and 65% (P 5 1.00) of patients having a VL measuring between 50 and 400 copies/mL were retested within 2 weeks in the DRV/r monotherapy group and in the 2 NRTI 1 DRV/r group, respectively, while from W56 to W96, 46% and 38% (P 5 .75) of VL measurements .50 copies/mL were retested, respectively. These results indicated no difference between the 2 randomized groups.
Overall, 51 patients experienced at least 1 VL .50 copies/mL from D0 to W48 (30 in the DRV/r monotherapy group and 21 in the 2 NRTI 1 DRV/r group; P 5 .21) and 79 patients from D0 to W96 (46 in the DRV/r monotherapy group and 33 in the 2 NRTI 1 DRV/r group; P 5 .07). Considering only the study visits planned in the protocol (without confirmation visits), 25 patients in each group had 1 or 2 VL results .50 copies/mL, while 21 (18.8%) patients in the DRV/r monotherapy group had 3 or more VL .50 copies/mL compared with 9 patients (8.0%) in the 2 NRTI 1 DRV/r group (P 5 .07).
Finally, among patients with VL ,50 copies/mL at W48, there was no difference in the proportions of patients with ultrasensitive VL ,1 copy/mL at W48 between the 2 groups; 63% (60 of 96) vs 66% (67 of 101) in the DRV/r monotherapy and tripledrug regimen, respectively (P 5 .66).
DISCUSSION
Boosted PI monotherapy has been proposed to be an antiretroviral option to avoid adverse effects related to the use of nucleosides while maintaining viral suppression for a majority of patients [3] [4] [5] [6] as well as to decrease cost of treatment. Nevertheless, this strategy cannot be considered an alternative to standard treatment in all patients; however, it has been suggested that such a monotherapy can be considered a tailored treatment in patients with a substantial period of viral suppression on HAART [7] . A major issue is then to identify patients who could benefit from such a monotherapy.
In the MONOI trial, results demonstrated the high efficacy rate of a darunavir monotherapy switch strategy in experienced patients, with an overall proportion of patients (.85%) maintaining therapeutic success by W48. In our study, however, being in the DRV/r monotherapy group was associated with an increased risk of virologic rebound, defined as 2 consecutive VL measurements .50 copies/mL according to current European and French guidelines, both at W48 and W96. In patients randomized to the DRV/r monotherapy group, in the short-term period (W48), having a single blip at D0 and/or 2 consecutive VL .1 copy/mL measurements at screening and D0 were predictive factors to virologic rebound. In the longer term (at W96), shorter time of prior ART exposure, higher HIV-1 DNA at D0, and ,100% adherence were associated with an increased risk of virologic rebound.
Some factors identified here in a strategy of switching to DRV/r monotherapy have already been identified in induction of PI monotherapy. Indeed, the MONARK study [12] had showed that nonresponders had significantly higher baseline HIV-1 DNA than responders in the lopinavir/ritonavir (LPV/ r) monotherapy arm. In the present study, while different factors have been associated with virologic rebound at W48 and W96, we can hypothesize that some of them are linked, such as baseline ultrasensitive VL and HIV-1 DNA level. Indeed, a low HIV-1 DNA level, reflecting HIV-1 reservoir, could be related to strongest control of residual viremia. In the same study of induction of LPV/r monotherapy [13] , adherence appeared also as a key factor associated with virologic failure. The occurrence of a baseline blip may be related to poor adherence in phase I of the study where DRV/r was introduced as part of the antiretroviral regimen. In our study, the level of pretherapeutic plasma VL was not associated with the virologic outcome in either arm as in another clinical study [14] . A first analysis of the MONOI trial showed that patients with a pretherapeutic VL ,100 000 copies/mL might, after achieving a durable period of HIV-1 RNA suppression, subsequently benefit from DRV/r monotherapy, but the outcome was different. The first analysis was focused on the primary endpoint of the trial, that is, therapeutic failure including virological failure (defined as 2 VL .400 copies/mL within 2 weeks), discontinuation, or treatment modification, and on a sustained virologic response (all HIV-1 RNA ,50 copies/mL through W48) [5] . In the present study the virological outcome mimics the definition of failure according to European and French recommendations. Finally, although we showed that DRV/r monotherapy group is associated with an increased risk of virologic rebound at W48 and at W96, patients who experienced a virologic rebound on DRV/r monotherapy had no evidence using population-based sequencing of emergence of new darunavir resistance mutations and were easily and quickly resuppressed.
In summary, because the risk of virologic failure is greater for DRV/r monotherapy than for triple therapy, patients for monotherapy should be selected carefully. The best candidates for DRV/r monotherapy include patients with excellent adherence who have consistently had plasma HIV-1 RNA levels ,50 copies/mL. The risk of virologic failure on DRV/r monotherapy appears to be lowest among those patients who have been on a suppressive regimen the longest prior to a switch to monotherapy. Longer ART duration may result in lower levels of residual viremia (plasma HIV-1 RNA detectable by single-copy assay) and lower HIV-1 proviral DNA levels. These 2 markers should be further characterized in prospective monotherapy studies to define more precisely their impact on virologic response and to search for clinical cutoffs.
Notes
